Current Status on Immunological Therapies for Type 1 Diabetes Mellitus

Xin, Griselda Lim Loo; Khee, Yap Pui; Ying, Tan; Chellian, Jestin; Gupta, Gaurav; Kunnath, Anil Philip; Nammi, Srinivas; Collet, Trudi; Hansbro, Philip M.; Dua, Kamal; Chellappan, Dinesh Kumar

doi:10.1007/s11892-019-1144-3

Cited by 18 publications

(11 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It stops and treats the disease in people with graft vs. host disease. Cyclosporine is recommended for refractory posterior uveitis and Behcet disease in the case of uveitis ( Pradier et al, 2019 ; Tapia et al, 2020a ; Ponticelli and Glassock, 2019 ; Xin et al, 2019 ; Sun et al, 2019 ).…”

Section: Immunosuppressive Drugsmentioning

confidence: 99%

Immunosuppressive Drugs

Hussain

Khan

2022

Encyclopedia of Infection and Immunity

View full text Add to dashboard Cite

Section: Immunosuppressive Drugsmentioning

confidence: 99%

Immunosuppressive Drugs

Hussain

Khan

2022

Encyclopedia of Infection and Immunity

View full text Add to dashboard Cite

“…2 However, some of these drugs remain restricted and patients do not tolerate them well; their long-term administration would trigger serious side effects, such as hypoglycemia, hepatotoxicity, weight gain, an abdominal bloating feeling, and diarrhea. 3 However, no specific agents have been identified as having specific effects on disease pathogenesis, and no licensed drugs can prevent the autoimmune impairment of ⊎-cells after diagnosis with T1DM. Thus, studies should focus on natural hypoglycemic materials for the management of T1DM.…”

Section: Introductionmentioning

confidence: 99%

Anti‐diabetic and gut microbiota modulation effects of sacha inchi (Plukenetia volubilis L.) leaf extract in streptozotocin‐induced type 1 diabetic mice

et al. 2022

View full text Add to dashboard Cite

BACKGROUND Sacha inchi (Plukenetia volubilis L.) tea has been used as an adjuvant treatment for diabetes in Pu’er, in the Yunnan province of China. The effects of sacha inchi tea on diabetes and the underlying mechanisms remain unknown. This study was conducted to investigate the influence of a water extract of sacha inchi (P. volubilis L.) leaves (PWE) on hypoglycemic activity and gut microbiota composition in mice with streptozotocin (STZ)‐induced type 1 diabetes mellitus (T1DM). During the 6 weeks of the study, T1DM mice were administered PWE intragastrically at 400 mg kg−1 body weight (BW) per day. RESULTS Treatment with PWE reduced excessive loss of BW and excessive intake of food. It significantly decreased blood glucose levels and improved oral glucose tolerance. The treatment caused protective histopathological transformations in sections of the pancreas, leading to decreased insulin resistance and improved insulin sensitivity. Treatment with PWE also significantly ameliorated disorders of the gut microbiota structure and increased the richness and diversity of intestinal microbial species in T1DM mice. At the genus level, the populations of several crucial bacteria, such as Akkermansia, Parabacteroides, and Muribaculum increased in the PWE treatment group but the abundance of Ruminiclostridium and Oscillibacter decreased. CONCLUSIONS Treatment with PWE can ameliorate hyperglycemic symptoms in STZ‐induced T1DM mice, and the anti‐diabetic effect of PWE was related to the amelioration of gut microbial structural disorder and the enrichment of functional bacteria. © 2022 Society of Chemical Industry.

show abstract

“…It is characterized by rapid onset, long duration, multiple complications, as well as thirst and polyuria. [ 1 ] T1DM accounts for approximately 90% of total diabetes in children and adolescents in Western countries and is the most common form of childhood diabetes in most parts of the world. [ 2 ] Although China's type 1 diabetes registration study has confirmed that China is one of the countries with the lowest incidence of type 1 diabetes in the world, due to the large population in China, the actual number of type 1 diabetes patients is not small.…”

Section: Introductionmentioning

confidence: 99%

Effect of sancai powder on glacemic variability of type 1 diabetes in China

Zhou

Zhang

et al. 2020

Medicine

View full text Add to dashboard Cite

Background: Type 1 diabetes mellitus (T1DM) is a chronic, immune-mediated disease characterized by the destruction of insulin producing cells and persistent hyperglycemia. At present, the drugs for type 1 diabetes mellitus can reduce blood glucose rapidly and effectively, but there are risks of hypoglycemia, large fluctuation of blood glucose, and chronic complications. Related research found that compared with continuous hyperglycemia, blood glucose fluctuations are more harmful to the chronic complications of diabetes. Blood glucose variation is closely related to the occurrence and development of chronic complications of diabetes. Sancai powder (SC) is made on the basis of 3 ancient Chinese medicine formulas, which has the effect of lowering blood glucose. There have been reports on the clinical study of SC in the treatment of diabetic patients, but there is no systematic evaluation of SC in the treatment of type 1 diabetes, so it is necessary to summarize and evaluate the existing evidence. Methods and analysis: This study will be conducted according to Preferred Reporting Items for Systematic Reviews and Meta-analysis Protocols. We will search 3 English databases and 4 Chinese databases. Two methodologically trained researchers will read titles, abstracts, and full texts, and independently select eligible literature based on inclusion and exclusion criteria. After assessing the risk of bias and extracting data, we will conduct a meta-analysis of the results, including: standard deviation of blood glucose level, coefficient of variation, mean blood glucose, postprandial blood glucose fluctuation, hypoglycemia index, glycated hemoglobin, overall impact rate, and adverse effects. The heterogeneity of the data will be tested by Cochrane x2 and I2. Based on reliable subgroup effect guidance, we established 3 hypotheses for subgroup analysis: disease status at baseline, duration of intervention, and type of concomitant medication. Sensitivity analysis will be carried out to assess the stability of the results. The publication bias assessment will then be performed by funnel plot analysis and Egger test. Finally, we will use the “grading, evaluation, development and evaluation of recommendations” system to assess the quality of evidence. Results: The results of this systematic review and meta-analysis will be published in a peer-reviewed journal. Conclusion: In our study, the evidence of SC in the treatment of reducing blood sugar fluctuation in type 1 diabetes will be comprehensively summarized and carefully evaluated. It will provide more options for clinical treatment of the disease. INPLASY registration number: INPLASY202050052

show abstract

Current Status on Immunological Therapies for Type 1 Diabetes Mellitus

Cited by 18 publications

References 79 publications

Immunosuppressive Drugs

Immunosuppressive Drugs

Anti‐diabetic and gut microbiota modulation effects of sacha inchi (Plukenetia volubilis L.) leaf extract in streptozotocin‐induced type 1 diabetic mice

Effect of sancai powder on glacemic variability of type 1 diabetes in China

Contact Info

Product

Resources

About